BioSpace

JULY 7, 2024

With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.

Drugs 120

Drugs Development Antibody Marketing 120

JAMA Internal Medicine

JULY 7, 2024

This cohort study compares treatment-associated weight loss and rates of gastrointestinal adverse events among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes in a clinical setting.

108

108

BioSpace

JULY 7, 2024

Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.

108

108

pharmaphorum

JULY 7, 2024

Novartis, Pfizer, Otsuka and Novo Nordisk have been called out for breaching the ABPI code of practice

115

115

Advertisement

Clinical Supply

BioSpace

JULY 7, 2024

Patient assistance programs may actually be a two-way street, providing patients with drugs and companies with data.

Drugs 84

Drugs 84

FDA Law Blog

JULY 7, 2024

By Gail H. Javitt — In its final rule on laboratory developed tests (LDTs) (see our prior blog here ), FDA acknowledged that “some laboratories may lack familiarity, experience, or existing infrastructure for complying with FDA requirements” and made multiple references to a “small entity compliance guidance” that the agency intended to publish to “provide additional guidance to small businesses.

Compliance 64

Compliance Manufacturing Regulation In-Vitro 64

Drug Patent Watch

JULY 7, 2024

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.

Drugs 59

Drugs Branding Marketing 59

VirTrial

JULY 7, 2024

Introduction Atopic Dermatitis (AD) is one of the most prevalent skin conditions worldwide. In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. This blog post explores the key measurement tools used in AD trials, specifically the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA),

Clinical Trials 52

Clinical Trials Clinical Trials Dermatology Trials 52

Drug Patent Watch

JULY 7, 2024

This chart shows the drugs with the most patents in France. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

Drugs 59

Drugs 59

VirTrial

JULY 7, 2024

Introduction Atopic Dermatitis (AD) is one of the most prevalent skin conditions worldwide. In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. This blog post explores the key measurement tools used in AD trials, specifically the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA),

Clinical Trials 52

Clinical Trials Clinical Trials Dermatology Trials 52

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

VirTrial

JULY 7, 2024

Introduction Atopic Dermatitis (AD) is one of the most prevalent skin conditions worldwide. In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. This blog post explores the key measurement tools used in AD trials, specifically the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA),

Clinical Trials 40

Clinical Trials Clinical Trials Dermatology Trials 40